Conference Coverage

Studies link GLP-1 agonists to progression of diabetic retinopathy


 

FROM ASRS 2023

What causes progression?

Whether worsening of retinopathy stems from rapid weight loss and acute reductions in concentrations of blood glucose or is a direct effect of GLP-1 agonists on the eye is unclear.

“That rapid reduction is thought to play some role,” Dr. Rahimy said. “But if you actually look out there in the basic science literature, it’s suggested that there are direct effects of these medications on the retina too. That being said, it’s suggested that they may be protective to the retina. And I think that’s where we’ve gotten a lot of mixed signals in our community between what we’ve seen on the basic science side vs. what we’re seeing on the real-world side.”

The study was independently funded. Dr. Rahimy reports consultancies or speakerships with AbbVie, Allergan, Apellis, Carl Zeiss, Genentech, and Google, and research support from Regeneron. Ms. Kapoor reports no relevant financial relationships.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

New guidelines on diabetes-related laboratory testing
MDedge Endocrinology
Pregnancy risks elevated in women with chronic pancreatitis
MDedge Endocrinology
Semaglutide use surges in U.S. adults with type 2 diabetes
MDedge Endocrinology
Plant-based or animal-based diet: Which is better?
MDedge Endocrinology
New approaches for diabetic keratopathy in the eye?
MDedge Endocrinology
Kombucha benefits type 2 diabetes, study suggests
MDedge Endocrinology
Skin reactions common at insulin pump infusion sites
MDedge Endocrinology
Higher occurrence of kidney stones with more added sugar
MDedge Endocrinology
Lawsuit alleges undisclosed stomach risks from Ozempic, Mounjaro
MDedge Endocrinology
Time-restricted eating gains for weight and glycemic control
MDedge Endocrinology